BioSphere advances on Embosphere filing:
This article was originally published in Clinica
BioSphere Medical says it is on track to file its Embosphere Microsphere technology for FDA clearance by the second quarter of 2002 for use in treating uterine fibroids. The firm has completed enrolment for a trial of the product involving 50 patients who will undergo hysterectomy for the condition. The phase II trial will measure complications, adverse events, changes in symptoms, quality of life and patient satisfaction. The Rockland, Massachusetts firm already has FDA clearance to market the technology for hypervascularised tumours and vascular malformations.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.